Glucophage Trio
Glimepiride · Metformin · Voglibose
Glimepiride and metformin tablets for type 2 diabetes. Glimepiride triggers insulin release, metformin cuts the liver's sugar output.
- Category
- Diabetes Management
- Active ingredients
- Glimepiride · Metformin · Voglibose
- Route
- Oral use
- Form
- Tablet
- Strengths
- 1mg + 0.2mg + 500mg
Prescription and consultation requirements for Glucophage Trio vary by destination and are determined by the fulfilment partner.
Glucophage Trio details
- Condition
- Type 2 Diabetes Mellitus
- Alternative names
- glimepiride, metformin, voglibose
- Therapeutic class
- Antidiabetic Combination
- Pharmacological class
- Sulfonylurea, Biguanide, Alpha-Glucosidase Inhibitor Combination
- Contraindications
- severe renal impairment; diabetic ketoacidosis; congestive heart failure
- Minor side effects
- diarrhoea; nausea; flatulence
- Moderate side effects
- hypoglycaemia; weight gain; metallic taste
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Merck
- Onset Time
- 1–2 weeks
- Duration
- 12–24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Alcohol; Contrast Media; NSAIDs
- Age restrictions
- Approved for adults.
Serious side effects
lactic acidosis, requires immediate medical attention; severe hypoglycaemia, requires immediate medical attention
Patient summary
Glimepiride and metformin tablets for type 2 diabetes. Glimepiride triggers insulin release, metformin cuts the liver's sugar output.
Mechanism of action
Stimulates pancreatic insulin, lowers liver glucose production, and slows intestinal carbohydrate breakdown concurrently.
Pregnancy and breastfeeding
Pregnancy: Avoid during pregnancy due to developmental risks. Breastfeeding: Not recommended.